Neurologic clinical trials - ORARIALS01 - Orphazyme ALS

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03491462

A multicenter, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of arimoclomol in amyotropic lateral sclerosis (ALS)

Drug

Drug: Arimoclomol, Placebo oral capsule

Trial Type

Interventional

Age Range

18 years or older

Condition

Amyotrophic Lateral Sclerosis (ALS)

Keywords

Amyotrophic Lateral Sclerosis | ALS | Orphazyme ALS | Arimoclomol